All In Biotech

Drug Trial Radar · NCT01475721

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma

Last checked: Nov 19, 2026Latest source record: Aug 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 11,751 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

11,751

Actual

Start

Nov 18, 2011

Primary completion

Jun 23, 2015

Study completion Jun 23, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Parexel
First posted
Nov 21, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone. ADVAIR™ and FLOVENT™ are trademarks of the GlaxoSmithKline Group of Companies.

Conditions

  • Asthma

Interventions

  • ADVAIR 100/50mcgDrug

    fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months

  • ADVAIR 250/50mcgDrug

    fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months

  • ADVAIR 500/50mcgDrug

    fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months

  • FLOVENT 100mcgDrug

    fluticasone propionate (100) twice daily (AM and PM) for 6 months

  • FLOVENT 250mcgDrug

    fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months

  • FLOVENT 500mcgDrug

    fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing an Event in the Composite Safety Endpoint of Serious Asthma Outcomes ( Asthma-related Hospitalization, Asthma-related Endotracheal Intubation, or Asthma-related Death)Time frame: From Day 1 up to 26 weeks
  2. Number of Participants Experiencing at Least One Asthma ExacerbationTime frame: From Day 1 up to 26 weeks

Locations

808 sites in 33 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Athens, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Florence, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Montgomery, Alabama

  • GSK Investigational Site

    Pell City, Alabama

  • GSK Investigational Site

    Scottsboro, Alabama

  • GSK Investigational Site

    Toney, Alabama

  • GSK Investigational Site

    Tuscaloosa, Alabama

  • GSK Investigational Site

    Chandler, Arizona

  • GSK Investigational Site

    Flagstaff, Arizona

  • GSK Investigational Site

    Goodyear, Arizona

  • GSK Investigational Site

    Green Valley, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Peoria, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Scottsdale, Arizona

  • GSK Investigational Site

    Sierra Vista, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Dinuba, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Granada Hills, California

  • GSK Investigational Site

    Harbor City, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    Huntington Park, California

  • GSK Investigational Site

    Lomita, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

Showing 40 of 808 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.